{"symbol":"JNJ","fiscalQuarter":"Q3-2012","reportDate":"2012-10-16","reportTime":"BMO","status":"reported","company":{"name":"Johnson & Johnson","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/JNJ/earnings/Q3-2012","postBrief":{"headline":"Johnson & Johnson Beats on EPS, Stock Up 1.38%","keyNumbers":[{"metric":"EPS","actual":"$1.25","expected":"N/A","surprise":"+3.91%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our performance this quarter, particularly in our pharmaceutical segment.","Our focus remains on innovation and improving patient outcomes."],"summary":"Management expressed satisfaction with the quarterly results, highlighting strong performance in key areas. They emphasized their commitment to innovation and patient care."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"The earnings report indicates that Johnson & Johnson is performing well, especially in its pharmaceutical division, which contributed to the positive EPS surprise. The stock reacted positively, rising 1.38% as investors responded favorably to the earnings beat. However, the lack of guidance leaves some uncertainty about future performance.","metaDescription":"Johnson & Johnson (JNJ) Q3 2012 earnings: EPS beat by 3.91%. Stock up 1.38%. Full breakdown."}}